IL6 and colorectal carcinoma: SYD has been found to reduce key inflammatory markers such as IL‐1, IL‐6, and TNF‐α, resulting in decreased tumor‐associated macrophage (TAM) infiltration and NF‐κB activation, thereby inhibiting Snail‐induced epithelial–mesenchymal transition (EMT) and subsequently CRC progression [33].